Oligonucleotide compounds for treatment of preeclampsia and other angiogenic disorders
AssigneesUniversity of Massachusetts, Beth Israel Deaconess Medical Center, Inc.
InventorsAnastasia Khvorova, Melissa Moore, Anton A. Turanov, Ananth Karumanchi
Life of this patent
Estimating the term…
Abstract
This disclosure relates to novel targets for angiogenic disorders. Novel oligonucleotides are also provided. Methods of using the novel oligonucleotides for the treatment of angiogenic disorders (e.g., preeclampsia) are also provided.
Claims49
A compound comprising an RNA molecule that is between 15 and 35 bases in length having a 5′ end, a 3′ end and complementarity to a target that binds to an intronic region of an mRNA encoding an sFLT1 protein, wherein the RNA molecule is fully chemically-stabilized and comprises a hydrophobic modification, wherein the compound selectively inhibits expression of the sFLT1 protein in a cell or organism.
A therapeutic compound, comprising an RNA molecule that is between 15 and 35 bases in length having a 5′ end, a 3′ end and complementarity to a target, that binds to an intronic region of an mRNA encoding an sFLT1 protein, wherein the RNA molecule is fully chemically-stabilized and comprises a hydrophobic modification, wherein the therapeutic compound selectively reduces expression of the sFLT1 protein, and wherein the therapeutic compound reduces one or more symptoms of preeclampsia (PE), postpartum PE, eclampsia or Hemolysis/Elevated Liver enzymes/Low Platelet count (HELLP) syndrome when administered to a subject in need thereof.
Dependencies are inferred from the claim text.